Nov. 12 at 5:18 PM
Xtant Medical Holdings (NYSE American:
$XTNT ) reported Q3 2025 results with revenue of
$33.3 million, up 19% year-over-year, achieving net income of
$1.3 million compared to a net loss of
$5.0 million in Q3 2024.
Xtant Medical is a B2i Digital Featured Company. View the full profile at https://b2idigital.com/xtant-medical.
The company expanded gross margin to 66.1% from 58.4% in the prior year quarter and generated
$4.6 million in operating cash flow versus a
$1.7 million use in Q3 2024. Adjusted EBITDA reached
$4.5 million, improving from a
$1.0 million loss in the prior year period. Management reaffirmed FY 2025 revenue guidance of
$131–
$135 million, representing 11%–15% growth over FY 2024.
The company's Q3 2025 performance metrics included:
• Revenue growth of 19% to
$33.3 million
• Gross margin expansion to 66.1%
• Return to profitability with net income of
$1.3 million (
$0.01/share)
• Positive adjusted EBITDA of
$4.5 million
• Cash generation from operations of
$4.6 million
• Reaffirmed FY 2025 guidance
Commenting on the quarterly results, Sean Browne, President and CEO, stated: "Our strong third-quarter results reflect continued focus on self-sustainability through positive free cash flow. New product launches and targeted sales-force investments are positioning us for accelerating biologics revenue growth while we manage expenses. We anticipate the sale of our non-core Coflex® and CoFix® assets and international businesses to Companion Spine will close by year-end, sharpening our focus on biologics innovation."
Recent business developments include the launch of CollagenX™, a bovine collagen particulate for surgical wound closure, and continued progress toward completing the Companion Spine transaction expected to close by year-end 2025.
Read the full release: https://investor.xtantmedical.com/news-releases/news-release-details/xtant-medical-reports-third-quarter-2025-financial-results
Xtant Medical is led by Chief Executive Officer Sean Browne, Chief Financial Officer Scott Neils and Chief Operating Officer Mark Schallenberger, who bring extensive expertise in medical device commercialization, corporate finance, and orthobiologic innovation.
For more information, visit https://www.xtantmedical.com. Investor inquiries: Kevin Gardner at LifeSci Advisors,
[email protected].
Disclosure: David Shapiro, CEO of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted XTNT stock, in line with B2i Digital's practice of investing alongside its Featured Companies. This post is not intended to solicit the sale of XTNT or any security, and it is not intended to offer any opinion on XTNT as an investment. Conduct your own research and consult with your own professional advisors prior to making any investment decisions. See the complete Disclosure in the Risks and Disclosures section of https://b2idigital.com/disclaimer.
